Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

about

Estimating global treatment toxicity burden from adverse-event data.

P2860

Q47641160-86AFA6D5-10C7-4AEC-8180-66275CFE1A46

P2860

Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

Item

http://www.wikidata.org/entity/Q38686511

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Using Delayed Toxicities to Re ...... Case Example using Bortezomib.

@en

type

Item

label

Using Delayed Toxicities to Re ...... Case Example using Bortezomib.

@en

prefLabel

Using Delayed Toxicities to Re ...... Case Example using Bortezomib.

@en

P1476

Using Delayed Toxicities to Re ...... Case Example using Bortezomib.

@en

P2093

Joseph M Unger

http://www.w3.org/2001/XMLSchema#string

Lori M Minasian

http://www.w3.org/2001/XMLSchema#string

Shing M Lee

http://www.w3.org/2001/XMLSchema#string

Yuan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.

The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254

Optimizing dosing of oncology drugs.

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

P304

484-489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07357907.2017.1340479

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dawn L Hershman

P577

2017-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28692317

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

about

P2860

P2860

Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921